Vinorelbine thiotepa in metastatic breast cancer: a large real-life retrospective study

References

• Ferlay J, Ervik M, Lam F, et al. Observatoire mondial du cancer. «Cancer Today». Lyon: Centre International de Recherche sur le Cancer; 2020.
   Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–3277. doi: 10.1200/JCO.2009.25.9820.
   PubMed Web of Science ®Google Scholar
• Lobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445–1451. doi: 10.1038/bjc.2015.127.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Chinot O, Metellus P, et al. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32(11):4655–4662.
   PubMed Web of Science ®Google Scholar
• Kuksis M, Gao Y, Tran W, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(6):894–904. doi: 10.1093/neuonc/noaa285.
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019;135:85–94. doi: 10.1016/j.critrevonc.2019.01.020.
   PubMed Web of Science ®Google Scholar
• Corti C, Antonarelli G, Criscitiello C, et al. Targeting brain metastases in breast cancer. Cancer Treat Rev. 2022;103:102324. doi: 10.1016/j.ctrv.2021.102324.
   PubMed Web of Science ®Google Scholar
• Steeg PS. The blood–tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021;18(11):696–714. doi: 10.1038/s41571-021-00529-6.
   PubMed Web of Science ®Google Scholar
• Deeken JF, Löscher W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663–1674. doi: 10.1158/1078-0432.CCR-06-2854.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi: 10.1056/NEJMoa1607303.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. doi: 10.1056/NEJMoa2028485.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Bardia A, Tolaney SM, et al. TROPiCS-02: a phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2– metastatic breast cancer. Future Oncol. 2020;16(12):705–715. doi: 10.2217/fon-2020-0163.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi: 10.1056/NEJMoa1914510.
   PubMed Web of Science ®Google Scholar
• Cortés J, Cescon DW, Rugo HS, et al. LBA16 KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann Oncol. 2021;32:S1289–S1290. doi: 10.1016/j.annonc.2021.08.2089.
   Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019.
   PubMed Web of Science ®Google Scholar
• Pellerino A, Internò V, Mo F, et al. Management of brain and leptomeningeal metastases from breast cancer. Int J Mol Sci. 2020;21(22):8534. doi: 10.3390/ijms21228534.
   PubMed Web of Science ®Google Scholar
• Gregory R, Smith I. Vinorelbine – a clinical review. Br J Cancer. 2000;82(12):1907–1913. doi: 10.1054/bjoc.2000.1203.
   PubMed Web of Science ®Google Scholar
• Xu Y-C, Wang H-X, Tang L, et al. A systematic review of vinorelbine for the treatment of breast cancer. Breast J. 2013;19(2):180–188. doi: 10.1111/tbj.12071.
   PubMed Web of Science ®Google Scholar
• Domenech GH, Vogel CL. A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer. 2001;2(2):113–128. doi: 10.3816/CBC.2001.n.016.
   PubMedGoogle Scholar
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceutical drugs (IARC monographs on the evaluation of the carcinogenic risks to humans, no. 50). Thiotepa. Lyon, France: International Agency for Research on Cancer; 1990.
   Google Scholar
• Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49(3):736–741.
   PubMed Web of Science ®Google Scholar
• Pace A, Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol. 2006;60(3):194–200. doi: 10.1016/j.critrevonc.2006.06.013.
   PubMed Web of Science ®Google Scholar
• Scordo M, Wang TP, Ahn KW, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;1(7):993–1003.
   Google Scholar
• Chahal J, Stopeck A, Clarke K, et al. Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series. Neurol Sci. 2015;36(9):1691–1693. doi: 10.1007/s10072-015-2259-1.
   PubMed Web of Science ®Google Scholar
• Comte A, Jdid W, Guilhaume MN, et al. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol. 2013;115(3):445–452. doi: 10.1007/s11060-013-1244-x.
   PubMed Web of Science ®Google Scholar
• Fabi A, Tonachella R, Savarese A, et al. A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol. 1995;6(2):187–189. doi: 10.1093/oxfordjournals.annonc.a059115.
   PubMed Web of Science ®Google Scholar
• Dabi Y, Thubert T, Fuchs F, et al. How is functioning the ethical review board «Comité d’Ethique Pour La Recherche En Obstétrique Et Gynécologie» (CEROG)? J Gynecol Obstet Hum Reprod. 2022;51(4):102352. doi: 10.1016/j.jogoh.2022.102352.
   PubMed Web of Science ®Google Scholar
• Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer. 2019;112:57–65. doi: 10.1016/j.ejca.2019.02.002.
   PubMed Web of Science ®Google Scholar
• Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the Phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219–225. doi: 10.1016/S1470-2045(07)70041-4.
   PubMed Web of Science ®Google Scholar
• Chan A, Verrill M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer. 2009;45(13):2253–2265. doi: 10.1016/j.ejca.2009.04.031.
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Penel N. Vinorelbine in breast cancer. Expert Opin Pharmacother. 2008;9(16):2901–2910. doi: 10.1517/14656566.9.16.2901.
   PubMed Web of Science ®Google Scholar
• Collet L, Péron J, Penault-Llorca F, et al. PARP inhibitors: a major therapeutic option in endocrine-receptor positive breast cancers. Cancers. 2022;14(3):599. doi: 10.3390/cancers14030599.
   PubMed Web of Science ®Google Scholar